Connor, Clark & Lunn Investment Management (CC&L)’s Crinetics Pharmaceuticals CRNX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-79,755	Closed	-$2.9M	–	1661
2026 Q1	$2.9M	Sell	79,755 -20,812	-21%	-$930K	0.01%	847
2025 Q4	$4.68M	Buy	100,567 +88,023	+702%	+$3.92M	0.01%	664
2025 Q3	$522K	Buy	+12,544	New	+$401K	﹤0.01%	1247
2025 Q1	–	Sell	-6,898	Closed	-$353K	–	1444
2024 Q4	$353K	Sell	6,898 -13,735	-67%	-$768K	﹤0.01%	1226
2024 Q3	$1.05M	Buy	20,633 +505	+3%	+$26K	0.01%	870
2024 Q2	$902K	Buy	+20,128	New	+$930K	﹤0.01%	875

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s CRNX Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2026, closing a stake of 79,755 shares — an estimated $2.9M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in CRNX in Q2 2024 and held it in 6 quarters. The position peaked at $4.68M in Q4 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Crinetics Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 79,755 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $2.9M.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Crinetics Pharmaceuticals in Q2 2024 and held it in 6 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Crinetics Pharmaceuticals position peaked at $4.68M in Q4 2025.
267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.